Redcliffe Hospital, Redcliffe, QLD, 4020, Australia.
Int Urol Nephrol. 2024 Feb;56(2):519-525. doi: 10.1007/s11255-023-03745-4. Epub 2023 Sep 21.
Urothelial carcinoma recurrence of an orthotopic neobladder created from bowel segment is a rare occurrence. The usage of bowel segments to create neobladder following cystectomy for urinary diversion is growing yet there still remains a large gap in the literature about recurrence in neobladder. We carry out the first systematic review to outline current details of urothelial cancer recurrences in a neobladder, diagnostic approach, management and long term prognosis.
We carried out a systematic review searching databases PubMed (MEDLINE), Scopus and Web of Science. Only studies reporting on urothelial carcinoma recurrence of the neobladder with or without multi-focal disease were reported. A quality assessment tool was utilized to ensure all studies met quality standards.
Fifteen studies were included in the systematic review meeting inclusion criteria. Fourteen of these studies were cases in men where pT3 disease was the most prevalent (29%). The most common symptomology was macroscopic haematuria seen in eight patients (53.33%). Management varied among cases and including adjuvant chemotherapy regimens and surgical interventions consisting of endoscopic resection to robotic neocystectomy and nephroureterectomy. Follow up period for these patients was up to 38 months and 55% of patients did not see a recurrence.
The nature of recurrence is hypothesised to be due to seeding of urothelial cells into the non-urothelial surfaces compatible for both implantation and growth. We present the first systematic review to report on recurrence rates and details of diagnosis and outcomes of various management regimes for urothelial carcinoma of the neobladder.
源自肠段的原位新膀胱的尿路上皮癌复发是一种罕见的情况。在进行尿流改道的膀胱切除术之后,使用肠段来创建新膀胱的方法越来越多,但关于新膀胱中复发的文献仍然存在很大差距。我们进行了首次系统评价,以概述新膀胱中尿路上皮癌复发的当前细节、诊断方法、管理和长期预后。
我们进行了系统评价,搜索了 PubMed(MEDLINE)、Scopus 和 Web of Science 数据库。仅报告了有或没有多灶性疾病的新膀胱尿路上皮癌复发的研究。使用质量评估工具确保所有研究均符合质量标准。
有 15 项研究符合系统评价的纳入标准,其中 14 项为男性病例,最常见的是 pT3 疾病(29%)。最常见的症状是 8 例患者(53.33%)出现肉眼血尿。病例的管理方法各不相同,包括辅助化疗方案和手术干预,包括内镜下切除、机器人新膀胱切除术和肾输尿管切除术。这些患者的随访时间最长可达 38 个月,55%的患者未复发。
复发的性质推测是由于尿路上皮细胞播散到非尿路上皮表面,这些表面既适合植入又适合生长。我们首次进行了系统评价,报告了新膀胱尿路上皮癌的复发率以及各种管理方案的诊断和结果的详细信息。